Elanco Q4 revenue $988M (-11% YoY), full year net loss $74M; guides FY2023 revenue $4.28-4.4B

Elanco Animal Health Inc

2022-FY EPS reported -$0.16 revenue$4,411,000,000

Q4 revenue $988M (-11% reported, -6% CER); Pet Health $423M (-14%), Farm Animal $552M (-9%).
Q4 reported net loss $54M ($0.11 loss per share); adjusted net income $95M, adjusted EPS $0.19.
Full year 2022 revenue $4,418M (-7% reported); reported net loss $74M; adjusted EBITDA $1,023M (23.2% margin).
FY2023 guidance: revenue $4,280-4,400M; adjusted EBITDA $920-1,000M; adjusted EPS $0.74-0.83.
Initiated JAK inhibitor submission to FDA; received FDA approval for Bexacat (feline diabetes); EPA approval for Advantage/K9 Advantix relaunch; Bovaer launch expected H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Elanco Animal Health Inc updated its the full year and fiscal quarter ended December 31, 2022 guidance (initiated).

Period: the full year and fiscal quarter ended December 31, 2022
Guidance: initiated
Result: reported results

Exact text from the filing

Attached as Exhibit 99.1 and incorporated by reference into this Item 2.02 is a copy of the press release, dated February 21, 2023, announcing the results of operations for the full year and fiscal quarter ended December 31, 2022 and guidance for the full year and first half of 2023

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

Elanco Animal Health Inc filing history →

Source: SEC EDGAR

accession 0001104659-23-023484

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.